ASTELLAS ANNOUNCES APPLICATION FOR THE IMMUNOSUPPRESSANT FK506 MODIFIED RELEASE FORMULATION IN JAPAN

Astellas Pharma Inc. today announced that it has submitted an application for the market authorization for the immunosuppressant FK506 Modified Release Formulation (generic name: tacrolimus) to the Pharmaceuticals and Medical Devices Agency (PMDA) with the proposed indication of "suppression of organ rejection in organ transplantation" and "suppression of graft rejection and GVHD in bone marrow transplantation" on May 29, 2006 in Japan.
JCN Network